Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

HC Wainwright Cuts Price For This Small Cap 'Reflecting Potential Pause In Hemophilia Program'

Published 22/08/2022, 20:50
Updated 22/08/2022, 21:40
© Reuters.  HC Wainwright Cuts Price For This Small Cap 'Reflecting Potential Pause In Hemophilia Program'

© Reuters. HC Wainwright Cuts Price For This Small Cap 'Reflecting Potential Pause In Hemophilia Program'

  • Earlier this month, Freeline Therapeutics Holdings PLC (NASDAQ: FRLN) reported 2Q22 earnings focusing on the pipeline's progress.
  • Notably, the company said it is evaluating strategic options for FLT180a for hemophilia B and is reviewing how to streamline operations, including but not limited to seeking a partner to enable the continuation of FLT180a through Phase 3 development.
  • Till the details on this potential pact are available, HC Wainwright is removing FLT180a from the model resulting in a price target of $15 from $20.
  • The company expects an update from the Phase 1/2 trial (MARVEL-1) evaluating FLT190 in Fabry disease in 2H22.
  • Dosing in the Phase 1/2 trial (GALILEO-1) evaluating FLT201 in Gaucher disease is expected to commence in 2H22, with initial data expected in 1H23.
  • HC Wainwright writes, "we look forward to continued progress on the lead programs to drive robust shareholder value over the next year."
  • Price Action: FRLN shares are down 3.16% at $0.92 on the last check Monday.
Latest Ratings for FRLN DateFirmActionFromTo
Feb 2022 Morgan Stanley (NYSE:MS)DowngradesOverweightEqual-Weight
Jan 2022Redburn PartnersUpgradesNeutralBuy
Nov 2021BTIGInitiates Coverage OnBuy
View More Analyst Ratings for FRLN

View the Latest Analyst Ratings

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.